

Theravance Biopharma, Inc.  
Form 8-K  
May 01, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K**

---

**Current Report Pursuant**  
**to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): **April 30, 2019**

---

**THERAVANCE BIOPHARMA, INC.**

(Exact Name of Registrant as Specified in its Charter)

---

**Cayman Islands**  
(State or Other Jurisdiction of  
Incorporation)

**001-36033**  
(Commission File Number)

**98-1226628**  
(I.R.S. Employer Identification  
Number)

**PO Box 309**

Edgar Filing: Theravance Biopharma, Inc. - Form 8-K

Ugland House, South Church Street

George Town, Grand Cayman, Cayman Islands KY1-1104

(650) 808-6000

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

(a) The 2019 Annual General Meeting of Shareholders (the Annual Meeting ) of Theravance Biopharma, Inc. (the Company ) was held on April 30, 2019.

(b) Shareholders holding 54,065,708 shares of capital stock, representing 96.36% of the total number of shares outstanding and entitled to vote at the Annual Meeting, were present in person or by proxy at the Annual Meeting.

The nominees listed below were elected Class II members of the Board of Directors with the respective numbers of shares voted set forth opposite their names:

Nominees	For	Against	Abstain	Broker Non-Votes
Rick E Winningham	49,149,630	402,435	2,020	4,511,623
<i>Percentage of Shares Voted</i>	<i>99.19</i>	<i>0.81</i>	<i>0.00</i>	
Robert V. Gunderson, Jr.	48,796,300	755,765	2,020	4,511,623
<i>Percentage of Shares Voted</i>	<i>98.47</i>	<i>1.53</i>	<i>0.00</i>	
Susan M. Molineaux	43,592,082	5,959,983	2,020	4,511,623
<i>Percentage of Shares Voted</i>	<i>87.97</i>	<i>12.03</i>	<i>0.00</i>	
Donal O Connor	49,416,078	135,987	2,020	4,511,623
<i>Percentage of Shares Voted</i>	<i>99.73</i>	<i>0.27</i>	<i>0.00</i>	

The shareholders ratified the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2019. The voting results are set forth below:

	For	Against	Abstain	Broker Non-Votes
Number of Shares Voted	53,615,727	421,412	28,569	
<i>Percentage of Shares Voted</i>	<i>99.17</i>	<i>0.78</i>	<i>0.05</i>	

For more information about the foregoing proposals, see the Company's Proxy Statement.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**THERAVANCE BIOPHARMA, INC.**

Date: May 1, 2019

By:

/s/ Bradford J. Shafer  
Bradford J. Shafer  
Executive Vice President, General Counsel and  
Secretary